原文标题： Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, Lilly 原文连结：https://tinyurl.com/2j9xw2ta 发布时间：February 5, 2026 9:33 PM GMT+8 记者署名：By Amina Niasse 原文内容： NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health ( HIMS.N) on Thursday began offering a much cheaper $49 compounded version of Novo Nordisk's (NOVOb.CO) new Wegovy weight-loss pill in a move that expands sales to many Americans but could undercut Novo's and Eli Lilly's (LLY.N) plans for the consumer market. （路透社纽约 5 日电）在线远程医疗公司 Hims and Hers Health 周四开始提供一种 价格仅为 49 美元的诺和诺德（Novo Nordisk）新减重药 Wegovy 的廉价配制版本 （compounded version）。此举扩大了对许多美国人的销售，但也可能削弱诺和诺 德与礼来（Eli Lilly）在消费市场的计画。 The news touched off a swift reaction on Wall Street as investors sold off Novo and Lilly shares, and the Danish drugmaker promised a legal challenge to the move by Hims. Novo shares fell 8.6%, while Lilly was off 6%. 此消息引起华尔街迅速反应，投资者抛售诺和诺德与礼来的股票，这家丹麦药商承诺 对 Hims 的举动提出法律挑战。诺和诺德股价下跌 8.6%，礼来下跌 6%。 Hims' pricing, $49 for the first month and $99 afterwards for those who purchase a five-month plan, makes their GLP-1 drug as affordable as monthly internet or streaming services in the U.S. It can offer access to treatment for many more of the estimated 200 million Americans who are overweight or obese. Hims 的定价为首月 49 美元，之後购买五个月方案者每月 99 美元，这使得他们 的 GLP-1 药物与美国每月的网路或串流媒体服务一样实惠。这可以为估计 2 亿名超 重或肥胖的美国人中的更多人提供治疗机会。 It is $100 less than Novo, which launched its pill in January at $149 for first-time users and $199 after that. Lilly is expected to launch its pill in April and has promised the Trump Administration affordable pricing including on its new TrumpRx site. 这比诺和诺德便宜了 100 美元。诺和诺德在 1 月推出了口服药，首用者价格为 149 美元，之後为 199 美元。礼来预计在 4 月推出口服药，并向川普政府承诺提供实惠 的价格，包括在其新的 TrumpRx 网站上。 Hims' move came after Novo warned on Wednesday that pricing pressure was unprecedented for its weight-loss medicines and dropped its full-year forecast . Novo shares on Thursday hit their lowest level since July 2021. Hims 的举动发生在诺和诺德周三发出警告之後，该公司称其减重药物面临前所未有 的定价压力，并下调了全年预测。诺和诺德股价周四创下 2021 年 7 月以来的最低 水平。 NOVO SAYS ITS PILL IS UNIQUE 诺和诺德称其口服药具有独特性 Novo CEO Mike Doustdar in a meeting with investors on Thursday said people spending $49 on a Hims' pill would be wasting their money and that Novo's pill uses unique technology that aids in the absorption of the medicine. 诺和诺德执行长 Mike Doustdar 周四在与投资者的会议上表示，花 49 美元买 Hims 口服药的人是在浪费钱，并强调诺和诺德的口服药采用了有助於药物吸收的独特技术。 Novo spokeswoman Ambre James-Brown described Hims' mass compounding as illegal . "Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework," she said. 诺和诺德发言人 Ambre James-Brown 将 Hims 的大规模配制行为描述为非法。她说 ：「诺和诺德将采取法律和监管行动，以保护患者、我们的知识产权以及美国金标准 药物审批框架的完整性。」 A Hims spokesperson said it has not compromised on safety or efficacy and that the company uses a technology based on liposomes that is intended to support absorption. Hims 发言人表示，公司在安全性和有效性上并未妥协，并称公司使用了一种基於脂质 体（liposomes）的技术，旨在支持药物吸收。 Analysts questioned if customers would get similar results on the cheaper pill but said it could drive a price war if compounders can provide an oral drug in large quantities. 分析师质疑客户使用廉价口服药是否能获得类似效果，但表示如果配制商能大量提供 口服药，这可能会引发价格战。 Hims has been tussling with Novo since it was allowed in 2023 by the U.S. Food and Drug Administration to sell versions of Novo's GLP-1 injectible drugs while the branded medicines were in short supply. Since then, it has made " personalized" copies of the branded drugs at different doses or regimens than those available from Novo and other drug companies. 自 2023 年美国食品药物管理局（FDA）允许在原厂药短缺期间销售诺和诺德 GLP-1 注射药物的版本以来，Hims 一直与诺和诺德纠缠不清。自那以後，它一直以与诺和 诺德及其他药商不同的剂量或疗程，制作原厂药的「个性化」副本。 These drugs are not FDA approved and are subject to limited agency oversight. They also do not go through clinical trials to prove efficacy. Novo's Wegovy pill showed weight loss of more than 16% in trials. 这些药物未经 FDA 批准，且受到的监管有限。它们也没有经过临床试验来证明有效性 。诺和诺德的 Wegovy 口服药在试验中显示减重幅度超过 16%。 "The status quo for months now has been a compounder can create a copycat version of a branded drug, so long as they make some kind of minor tweak that they believe or they argue benefits specific patient groups," said TD Cowen analyst Michael Nedelcovych. TD Cowen 分析师 Michael Nedelcovych 表示：「几个月来的现状是，配制商可以创 建原厂药的仿制版本，只要他们进行某种细微调整，并认为或辩称这有利於特定的患 者群体。」 HIMS MAKES CASE FOR MORE CHOICE HIMS 提出更多选择的理由 Hims said the treatment can be tailored for patients aiming to mitigate side effects or who prefer a pill over the injectable option. Semaglutide is the main ingredient in the new Wegovy pill as well as injectable Wegovy and Ozempic. Hims 表示，治疗方案可以为旨在减轻副作用或比起注射更偏好口服药的患者量身定制 。司美格鲁肽（Semaglutide）是新 Wegovy 口服药以及注射型 Wegovy 和 Ozempic 的主要成分。 "We're excited to find ways to continue bringing branded treatments to the platform across specialties. More choice on the platform is the best thing for customers everywhere," said Hims CEO Andrew Dudum in a statement. Hims 执行长 Andrew Dudum 在声明中表示：「我们很高兴能找到方法，继续将各专 业领域的原厂治疗方案带到平台上。平台上更多的选择对各地的客户来说都是最好的 事情。」 Novo and Hims had a partnership in 2025 allowing the telehealth company to offer injectable Wegovy, but the two companies walked away with Novo saying Hims had wrongfully marketed versions of its medicine. Dudum accused Novo of attempting to control how clinicians at Hims make decisions. 诺和诺德与 Hims 在 2025 年曾有过合作，允许这家远程医疗公司提供注射型 Wegovy ，但两家公司後来分道扬镳，诺和诺德称 Hims 错误地销售其药物版本。Dudum 则指 责诺和诺德试图控制 Hims 临床医生的决策。 By tailoring its offering for patients with side effects or an aversion to needles, Gaston Kroub, a patent lawyer in New York, said Hims is positioning the oral product as another personalized option, widening the scope of personalization under the FDA’s framework. 纽约专利律师 Gaston Kroub 表示，透过为有副作用或畏惧针头的患者定制产品， Hims 将口服产品定位为另一种个性化选择，扩展了 FDA 框架下个性化的范畴。 "HIMS has shown a willingness to go as close to the line as possible,” he said. “It’s a strategy of saying, ‘All right, if we pop our head over the barbed wire fence, is anybody going to take a shot?’” 他说：「Hims 展现了尽可能接近底线的意愿。这是一种策略，就像在说：『好吧 ，如果我们把头探出铁丝网，会有人开枪吗？』」 Novo launched the drug in the beginning of January and has seen strong demand in the U.S., where it is available on its cash-pay direct-to-consumer website. 诺和诺德在 1 月初推出了该药物，并在美国看到了强劲需求，该药物可在其现金支付的 直接面向消费者（DTC）网站上购买。 Novo Chief Financial Officer Karsten Munk Knudsen told Reuters on Wednesday that the drugmaker is frustrated by continued mass marketing of compounded drugs, and said it was up to the U.S. regulator and politicians to address this. 诺和诺德财务长 Karsten Munk Knudsen 周三告诉路透社，药商对配制药的持续大规 模营销感到沮丧，并表示这取决於美国监管机构和政治家来解决。 The FDA in September issued a warning to Hims regarding its marketing of compounded semaglutide, stating claims like "same active ingredient as Ozempic and Wegovy" are misleading, as compounded drugs are not FDA-approved. FDA 在 9 月曾就配制司美格鲁肽的营销向 Hims 发出警告，称「与 Ozempic 和 Wegovy 具有相同活性成分」等说法具有误导性，因为配制药未经 FDA 批准。 LILLY PILL IS NEXT UP 礼来口服药即将登场 In addition to U.S. pricing pressure, Novo is girding for competition from Eli Lilly on the oral weight-loss front as the Indianapolis-based drugmaker expects to launch its own pill in the second quarter. 除了美国的定价压力外，诺和诺德还准备在口服减重领域迎接来自礼来的竞争，这家 总部位於印第安纳波利斯的药商预计将在第二季度推出自己的口服药。 Some analysts said Lilly's pill, an experimental GLP-1, could be a next target for compounded copies. Compounding, in which pharmacies mix ingredients for specialized medicines or to copy a drug but at different dosages, has flourished as Americans chase cheaper prices for drugs. 一些分析师表示，礼来的口服药（一种实验性 GLP-1）可能是配制仿制药的下一个 目标。配制（药剂师混合成分以制作专门药物或模仿药物但剂量不同）在美国人追 求更廉价药价的背景下蓬勃发展。 Hims declined to comment on the drug. Lilly did not have an immediate comment. Hims 拒绝就该药物发表评论。礼来没有立即置评。 In 2025, Hims doubled the size of its facility in New Albany, Ohio. The company said on Thursday the expansion allows Hims to provide treatments at a lower price. 2025 年，Hims 将其在俄亥俄州新奥尔巴尼（New Albany）的设施规模扩大了一倍。 该公司周四表示，扩建让 Hims 能以更低的价格提供治疗。 心得/评论： https://trumprx.gov/ 川普药局压药价加上Hims竞争 以及专利到期问题 2026年开始 中国、加拿大、巴西、印度等国 Novo Nordisk诺和诺德的Semaglutide司美格鲁肽专利将会到期 这些国家的药厂的学名药已经做好在等了 诺和诺德的Semaglutide司美格鲁肽的专利大约在2006年就已经在全球范围内陆续申请 --

※ 发信站: 批踢踢实业坊(ptt.cc), 来自: 180.177.12.128 (台湾) ※ 文章网址: https://webptt.com/cn.aspx?n=bbs/Stock/M.1770352664.A.B3C.html